These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. PEA-15 engages in allosteric interactions using a common scaffold in a phosphorylation-dependent manner. Ikedife J; He J; Wei Y Sci Rep; 2022 Jan; 12(1):116. PubMed ID: 34997083 [TBL] [Abstract][Full Text] [Related]
3. The anti-apoptotic protein PEA-15 is a tight binding inhibitor of ERK1 and ERK2, which blocks docking interactions at the D-recruitment site. Callaway K; Abramczyk O; Martin L; Dalby KN Biochemistry; 2007 Aug; 46(32):9187-98. PubMed ID: 17658892 [TBL] [Abstract][Full Text] [Related]
4. Substantial conformational change mediated by charge-triad residues of the death effector domain in protein-protein interactions. Twomey EC; Cordasco DF; Kozuch SD; Wei Y PLoS One; 2013; 8(12):e83421. PubMed ID: 24391764 [TBL] [Abstract][Full Text] [Related]
5. Recognition of ERK MAP kinase by PEA-15 reveals a common docking site within the death domain and death effector domain. Hill JM; Vaidyanathan H; Ramos JW; Ginsberg MH; Werner MH EMBO J; 2002 Dec; 21(23):6494-504. PubMed ID: 12456656 [TBL] [Abstract][Full Text] [Related]
6. Profound conformational changes of PED/PEA-15 in ERK2 complex revealed by NMR backbone dynamics. Twomey EC; Cordasco DF; Wei Y Biochim Biophys Acta; 2012 Dec; 1824(12):1382-93. PubMed ID: 22820249 [TBL] [Abstract][Full Text] [Related]
7. Phosphorylation of PEA-15 switches its binding specificity from ERK/MAPK to FADD. Renganathan H; Vaidyanathan H; Knapinska A; Ramos JW Biochem J; 2005 Sep; 390(Pt 3):729-35. PubMed ID: 15916534 [TBL] [Abstract][Full Text] [Related]
8. Phosphoprotein enriched in astrocytes (PEA)-15: a potential therapeutic target in multiple disease states. Greig FH; Nixon GF Pharmacol Ther; 2014 Sep; 143(3):265-74. PubMed ID: 24657708 [TBL] [Abstract][Full Text] [Related]
9. Structure of ERK2 bound to PEA-15 reveals a mechanism for rapid release of activated MAPK. Mace PD; Wallez Y; Egger MF; Dobaczewska MK; Robinson H; Pasquale EB; Riedl SJ Nat Commun; 2013; 4():1681. PubMed ID: 23575685 [TBL] [Abstract][Full Text] [Related]
10. Quantifying ERK2-protein interactions by fluorescence anisotropy: PEA-15 inhibits ERK2 by blocking the binding of DEJL domains. Callaway K; Rainey MA; Dalby KN Biochim Biophys Acta; 2005 Dec; 1754(1-2):316-23. PubMed ID: 16324895 [TBL] [Abstract][Full Text] [Related]
11. FADD adaptor and PEA-15/ERK1/2 partners in major depression and schizophrenia postmortem brains: basal contents and effects of psychotropic treatments. García-Fuster MJ; Díez-Alarcia R; Ferrer-Alcón M; La Harpe R; Meana JJ; García-Sevilla JA Neuroscience; 2014 Sep; 277():541-51. PubMed ID: 25075716 [TBL] [Abstract][Full Text] [Related]
12. The death effector domain protein PEA-15 prevents nuclear entry of ERK2 by inhibiting required interactions. Whitehurst AW; Robinson FL; Moore MS; Cobb MH J Biol Chem; 2004 Mar; 279(13):12840-7. PubMed ID: 14707138 [TBL] [Abstract][Full Text] [Related]
14. Molecular basis of death effector domain chain assembly and its role in caspase-8 activation. Singh N; Hassan A; Bose K FASEB J; 2016 Jan; 30(1):186-200. PubMed ID: 26370846 [TBL] [Abstract][Full Text] [Related]